Journal
GENETICS IN MEDICINE
Volume 20, Issue 9, Pages 910-917Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/gim.2017.219
Keywords
cell-free DNA sequencing; copy-number variant; incidental finding; prenatal screening; sex-chromosome aneuploidy
Categories
Funding
- NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG200400] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Circulating DNA fragments in a pregnant woman's plasma derive from three sources: placenta, maternal bone marrow, and fetus. Prenatal sequencing to noninvasively screen for fetal chromosome abnormalities is performed on this mixed sample; results can therefore reflect the maternal as well as the fetoplacental DNA. Although it is recommended that pretest counseling include the possibility of detecting maternal genomic imbalance, this seldom occurs. Maternal abnormalities that can affect a prenatal screening test result include disorders that affect the size and metabolism of DNA, such as B12 deficiency, autoimmune disease, and intrahepatic cholestasis of pregnancy. Similarly, maternal tumors, both benign and malignant, can release DNA fragments that contain duplications or deletions. Bioinformatics algorithms can subsequently interpret the raw sequencing data incorrectly, resulting in false-positive test reports of fetal monosomies or test failures. Maternal sex-chromosome abnormalities, both constitutional and somatic, can generate results that are discordant with fetal ultrasound examination or karyotype. Maternal copy-number variants and mosaicism for autosomal aneuploidies can also skew interpretation. A maternal etiology should therefore be considered in the differential diagnosis of prenatal cell-free DNA test failures, false-positive and falsenegative sequencing results. Further study is needed regarding the clinical utility of reporting maternal incidental findings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available